Beta-hCG

Beta-hCG (beta human chorionic gonadotropin) is a hormone protein normally produced during pregnancy by placental tissue. It is measured in blood or urine and is also used as a tumor marker because certain cancers, particularly germ cell tumors of the testis or ovary and gestational trophoblastic disease, can secrete it. In the context of an unexplained mass or effusion, beta-hCG helps doctors distinguish between possible cancer types.

Origin

Human chorionic gonadotropin was first identified in the 1920s by Ascheim and Zondek in the urine of pregnant women. The hormone has two subunits (alpha and beta); the beta subunit is unique to hCG and was isolated in the early 1970s, allowing specific immunoassays that are now standard in oncology and obstetrics.

Significance in Asbestos Context

Patients being worked up for mesothelioma or another suspected chest or abdominal cancer often have a panel of tumor markers drawn, and beta-hCG is sometimes among them. Mesothelioma does not typically produce beta-hCG, so an elevated level usually points the workup toward a different diagnosis, for example, a germ cell tumor that has spread to the chest or abdomen, or, in women of reproductive age, pregnancy itself, which must be ruled out before imaging with contrast or certain treatments. For patients, beta-hCG is most useful as a 'rule-out' marker that helps confirm the diagnosis is in fact mesothelioma rather than a cancer that can look similar on scans. Once mesothelioma is confirmed, beta-hCG generally has no role in tracking the disease.

Example Sentence

Before starting chemotherapy for her peritoneal mesothelioma, the oncologist ordered a beta-hCG to rule out pregnancy and to confirm the mass was not a germ cell tumor.

Related Terms

Tumor Markers, Mesothelin, SMRP, CA-125, Differential Diagnosis, Immunohistochemistry

Notes

• Ask your oncologist which tumor markers were drawn and what each one showed; request copies for your records, since marker patterns help document why mesothelioma, and not another cancer, was diagnosed.
• If beta-hCG comes back elevated, ask whether additional imaging or testing (such as testicular ultrasound in men, or pelvic evaluation in women) is needed before assuming the diagnosis is mesothelioma.
• Women of reproductive age should expect a beta-hCG before CT scans with contrast, biopsies, or chemotherapy; this is routine safety practice, not a sign of diagnostic uncertainty.
• Keep the full pathology report and immunohistochemistry panel. These, rather than beta-hCG, are what confirm mesothelioma for both medical care and any legal claim.